Jazz Pharmaceuticals acquires UK medical cannabis firm for $7.2bn
04-02-2021
Hikma enters settlement agreement with Jazz to sell Xyrem generic
07-04-2017
Kieferpix / iStockphoto.com
The US Court of Appeals for the Federal Circuit has rejected Jazz Pharmaceuticals’ attempt to revive patents covering its narcolepsy drug Xyrem (sodium oxybate).
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Jazz Pharmaceuticals, US Court of Appeals for the Federal Circuit, generics, Xyrem, Amneal, inter partes reviews, IPRs, PTAB
